Modulation of tcf7l2 expression alters behavior in mice

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Savic, Daniel ^a   Distler, Margaret G ^a   Sokoloff, Greta ^a   Shanahan, Nancy A ^a   Dulawa, Stephanie C ^a   Palmer, Abraham A ^a   Nobrega, Marcelo A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR 7 LIKE 2; GLUCOSE; TCF7L2 PROTEIN, MOUSE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; COMORBIDITY; CONDITIONING; CONTROLLED STUDY; ENDOPHENOTYPE; FEAR; GENETIC SUSCEPTIBILITY; GLUCOSE METABOLISM; LEARNING; LIGHT DARK CYCLE; MODULATION; MOUSE; NONHUMAN; NULL ALLELE; OPEN FIELD TEST; PHENOTYPE; PREPULSE INHIBITION; PROTEIN EXPRESSION; ANIMAL; GENETIC PREDISPOSITION; GENETICS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; SCHIZOPHRENIA;

ANIMALIA; MUS;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; COMORBIDITY; DIABETES MELLITUS, TYPE 2; ENDOPHENOTYPES; FEAR; GENETIC PREDISPOSITION TO DISEASE; GLUCOSE; MICE; SCHIZOPHRENIA; TRANSCRIPTION FACTOR 7-LIKE 2 PROTEIN;

EID: 80055064641     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026897     Document Type: Article

References (42)

1. Huang CJ, Chiu HC, Lee MH, Wang SY, (2011) Prevalence and incidence of anxiety disorders in diabetic patients: a national population-based cohort study. Gen Hosp Psychiatry 33: 8-15.
2. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ, (2001) The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 24: 1069-1078.
3. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL, (1996) Diabetes mellitus in schizophrenic patients. Compr Psychiatry 37: 68-73.
4. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, et al. (2000) Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 26: 903-912.
5. Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV, (2002) Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 70: 19-26.
6. Subramaniam M, Chong SA, Pek E, (2003) Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 48: 345-347.
7. Collins MM, Corcoran P, Perry IJ, (2009) Anxiety and depression symptoms in patients with diabetes. Diabet Med 26: 153-161.
8. Grigsby AB, Anderson RJ, Freedland KE, Clouse RE, Lustman PJ, (2002) Prevalence of anxiety in adults with diabetes: a systematic review. J Psychosom Res 53: 1053-1060.
9. Egede LE, Zheng D, Simpson K, (2002) Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care 25: 464-470.
10. Khuwaja AK, Lalani S, Dhanani R, Azam IS, Rafique G, et al. (2010) Anxiety and depression among outpatients with type 2 diabetes: A multi-centre study of prevalence and associated factors. Diabetol Metab Syndr 2: 72.
11. Medved V, Jovanovic N, Knapic VP, (2009) The comorbidity of diabetes mellitus and psychiatric disorders. Psychiatr Danub 21: 585-588.
12. Bouwman V, Adriaanse MC, van 't Riet E, Snoek FJ, Dekker JM, et al. (2010) Depression, anxiety and glucose metabolism in the general dutch population: the new Hoorn study. PLoS One 5: e9971.
13. Gough SC, O'Donovan MC, (2005) Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J Psychopharmacol 19: 47-55.
14. Lin PI, Shuldiner AR, (2010) Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr Res 123: 234-243.
15. Holt RI, Peveler RC, Byrne CD, (2004) Schizophrenia, the metabolic syndrome and diabetes. Diabet Med 21: 515-523.
16. Lorenz WF, (1922) Sugar tolerance in dementia praecox and other mental disorders. Arch Neurol Psychiatry 8: 184-186.
17. Kasanin J, (1926) The blood sugar curve in mental disease, II: the schizophrenic (dementia praecox) group. Arch Neurol Psychiatry 16: 414-419.
18. Braceland FJ, Meduna LJ, Vaichulis JA, (1945) Delayed action of insulin in schizophrenia. American Journal of Psychiatry 102: 108-110.
19. Freeman H, (1946) Resistance to insulin in mentally disturbed soldiers. Arch Neurol Psychiatry 56: 74-78.
20. Kooy FH, (1919) Hyperglycemia in mental disorders. Brain 42: 214-288.
21. Ryan MC, Collins P, Thakore JH, (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160: 284-289.
22. Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, et al. (2006) Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: A preliminary report. Can J Psychiatry 51: 382-386.
23. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH, (2007) Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 24: 481-485.
24. Dasgupta A, Singh OP, Rout JK, Saha T, Mandal S, (2010) Insulin resistance and metabolic profile in antipsychotic naive schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 34: 1202-1207.
25. Guest PC, Wang L, Harris LW, Burling K, Levin Y, et al. (2010) Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol Psychiatry 15: 118-119.
26. Fernandez-Egea E, Miller B, Bernardo M, Donner T, Kirkpatrick B, (2008) Parental history of type 2 diabetes in patients with nonaffective psychosis. Schizophr Res 98: 302-306.
27. Mukherjee S, Schnur DB, Reddy R, (1989) Family history of type 2 diabetes in schizophrenic patients. Lancet 1: 495.
28. Hansen T, Ingason A, Djurovic S, Melle I, Fenger M, et al. (2011) At-Risk Variant in TCF7L2 for Type II Diabetes Increases Risk of Schizophrenia. Biol Psychiatry 70: 59-63.
29. Lyssenko V, (2008) The transcription factor 7-like 2 gene and increased risk of type 2 diabetes: an update. Curr Opin Clin Nutr Metab Care 11: 385-392.
30. Cauchi S, El Achhab Y, Choquet H, Dina C, Krempler F, et al. (2007) TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis. J Mol Med 85: 777-782.
31. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, et al. (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38: 320-323.
32. Savic D, Ye H, Aneas I, Park SY, Bell GI, et al. (2011) Alterations in TCF7L2 expression define its role as a key regulator of glucose metabolism. Genome Res.
33. Ponder CA, Kliethermes CL, Drew MR, Muller J, Das K, et al. (2007) Selection for contextual fear conditioning affects anxiety-like behaviors and gene expression. Genes Brain Behav 6: 736-749.
34. Dulawa SC, Geyer MA, (1996) Psychopharmacology of prepulse inhibition in mice. Chin J Physiol 39: 139-146.
35. Mansbach RS, Geyer MA, Braff DL, (1988) Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology (Berl) 94: 507-514.
36. Marschner A, Kalisch R, Vervliet B, Vansteenwegen D, Buchel C, (2008) Dissociable roles for the hippocampus and the amygdala in human cued versus context fear conditioning. J Neurosci 28: 9030-9036.
37. Hemsley DR, (2005) The development of a cognitive model of schizophrenia: placing it in context. Neurosci Biobehav Rev 29: 977-988.
38. Balu DT, Carlson GC, Talbot K, Kazi H, Hill-Smith TE, et al. (2010) Akt1 deficiency in schizophrenia and impairment of hippocampal plasticity and function. Hippocampus.
39. Pohlack ST, Nees F, Ruttorf M, Witt SH, Nieratschker V, et al. (2011) Risk variant for schizophrenia in the neurogranin gene impacts on hippocampus activation during contextual fear conditioning. Mol Psychiatry.
40. MacDonald BT, Tamai K, He X, (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17: 9-26.
41. Clevers H, (2006) Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480.
42. Moon RT, Kohn AD, De Ferrari GV, Kaykas A, (2004) WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5: 691-701.